CY1119455T1 - Θεραπεια διαταραχων του αυτιστικου φασματος με τη χρηση γλυκυλ-l-2-μεθυλοπρολυλ-l-γλουταμινικου οξεος - Google Patents

Θεραπεια διαταραχων του αυτιστικου φασματος με τη χρηση γλυκυλ-l-2-μεθυλοπρολυλ-l-γλουταμινικου οξεος

Info

Publication number
CY1119455T1
CY1119455T1 CY20171101074T CY171101074T CY1119455T1 CY 1119455 T1 CY1119455 T1 CY 1119455T1 CY 20171101074 T CY20171101074 T CY 20171101074T CY 171101074 T CY171101074 T CY 171101074T CY 1119455 T1 CY1119455 T1 CY 1119455T1
Authority
CY
Cyprus
Prior art keywords
treatment
spectrum disorders
glycyl
disorder
autistic
Prior art date
Application number
CY20171101074T
Other languages
English (en)
Inventor
Larry Glass
Michael John Bickerdike
Michael Frederick Snape
Original Assignee
Neuren Pharmaceuticals Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuren Pharmaceuticals Limited filed Critical Neuren Pharmaceuticals Limited
Publication of CY1119455T1 publication Critical patent/CY1119455T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει ενώσεις, συνθέσεις και μεθόδους για τη θεραπεία Διαταραχών του Αυτιστικού Φάσματος (ΔΑΦ) με τη χρήση γλυκυλ-2-μεθυλοπρολυλ-γλουταμινικού οξέος (G-2-MePE) και αναλόγων αυτού. Οι Διαταραχές του Αυτιστικού Φάσματος περιλαμβάνουν τον Αυτισμό, την Αυτιστική Διαταραχή, το Σύνδρομο Άσπεργκερ, την Παιδική Αποδιοργανωτική Διαταραχή, τη Διάχυτη Αναπτυξιακή Διαταραχή - Μη Προσδιοριζόμενη Αλλιώς (ΔΑΔ-ΜΠΑ), το Σύνδρομο Εύθραυστου Χ και το Σύνδρομο Rett. Οι συνθέσεις που περιέχουν τις ενώσεις περιλαμβάνουν υδατοδιαλυτά σκευάσματα, μικρο-γαλακτώματα νερού σε έλαιο, αδρά γαλακτώματα νερού σε έλαιο, υγρούς κρυστάλλους νερού σε έλαιο, νανοκάψουλες, δισκία και από του στόματος χορηγούμενες γέλες. Οι ενώσεις και οι συνθέσεις της παρούσας εφεύρεσης μπορούν να χορηγηθούν ενδοφλεβίως, ενδοκοιλιακά, παρεντερικά ή από του στόματος και μπορούν να είναι αποτελεσματικές στη θεραπεία του νευροεκφυλισμού, στην προαγωγή της νευρολογικής λειτουργίας, στη θεραπεία της επιληπτικής δραστηριότητας και άλλων συμπτωμάτων των ΔΑΦ και μπορούν να παρατείνουν τη ζωή σε ζώα, συμπεριλαμβανομένων των ανθρώπινων όντων που έχουν Διαταραχές του Αυτιστικού Φάσματος.
CY20171101074T 2011-01-27 2017-10-12 Θεραπεια διαταραχων του αυτιστικου φασματος με τη χρηση γλυκυλ-l-2-μεθυλοπρολυλ-l-γλουταμινικου οξεος CY1119455T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161462141P 2011-01-27 2011-01-27
US201161492248P 2011-06-01 2011-06-01
PCT/US2012/000047 WO2012102832A1 (en) 2011-01-27 2012-01-27 Treatment of autism spectrum disorderes using glycyl-l-2-methylprolyl-l-glutamic acid

Publications (1)

Publication Number Publication Date
CY1119455T1 true CY1119455T1 (el) 2018-04-04

Family

ID=46581110

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171101074T CY1119455T1 (el) 2011-01-27 2017-10-12 Θεραπεια διαταραχων του αυτιστικου φασματος με τη χρηση γλυκυλ-l-2-μεθυλοπρολυλ-l-γλουταμινικου οξεος

Country Status (19)

Country Link
US (2) US9708366B2 (el)
EP (1) EP2667715B1 (el)
JP (3) JP6348283B2 (el)
AU (1) AU2012209466C1 (el)
BR (1) BR112013018898B1 (el)
CA (1) CA2823218C (el)
CO (1) CO6791613A2 (el)
CY (1) CY1119455T1 (el)
DK (1) DK2667715T3 (el)
ES (1) ES2641880T3 (el)
HR (1) HRP20171478T1 (el)
HU (1) HUE036637T2 (el)
IL (1) IL227669B (el)
LT (1) LT2667715T (el)
PL (1) PL2667715T3 (el)
PT (1) PT2667715T (el)
RS (1) RS56461B1 (el)
SI (1) SI2667715T1 (el)
WO (1) WO2012102832A1 (el)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9708366B2 (en) * 2011-01-27 2017-07-18 Neuren Pharmaceuticals Ltd. Treatment of fragile X syndrome using glycyl-L-2-methylprolyl-L-glutamate
US10039777B2 (en) 2012-03-20 2018-08-07 Neuro-Lm Sas Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
EP2928300A4 (en) * 2012-11-28 2016-07-13 Neuren Pharmaceuticals Ltd TREATMENT OF AUTISTIC SPECTRUM DISORDERS USING GLYCYL-L-2-METHYLPROLYL-L-GLUTAMIC ACID
LT3024463T (lt) * 2013-07-25 2020-07-10 Neuren Pharmaceuticals Limited Neuroapsauginiai bicikliniai junginiai ir jų panaudojimo būdai autizmo spektro sutrikimų ir neuroliginių vystymosi sutrikimų gydymui
EP3049428B1 (en) 2013-09-23 2018-11-07 Dr. August Wolff GmbH & Co. KG Arzneimittel Anti-inflammatory tripeptides
AU2015271652B2 (en) * 2014-06-06 2021-05-27 Wah Chin Boon Methods of treating neurodevelopmental diseases and disorders
RU2608444C1 (ru) * 2015-10-02 2017-01-18 Закрытое Акционерное Общество "Алмаз Фарм" Средство для лечения и профилактики расстройств аутистического спектра
JP6694216B2 (ja) 2015-10-14 2020-05-13 学校法人 久留米大学 グレリンを有効成分として含有するレット症候群（ｒｔｔ）の予防・治療剤
US11972336B2 (en) 2015-12-18 2024-04-30 Cognoa, Inc. Machine learning platform and system for data analysis
AU2017261287A1 (en) * 2016-05-04 2018-10-25 Neurotrope Bioscience, Inc. Methods and compositions for treatment of Rett syndrome
JP7114604B2 (ja) 2017-01-20 2022-08-08 プリレニア ニューロセラピューティクス リミテッド 脆弱ｘ症候群の治療のためのプリドピジンの使用
GB2575740A (en) 2017-02-09 2020-01-22 Congoa Inc Platform and system for digital personalized medicine
CA3128037A1 (en) * 2019-02-01 2020-08-06 Revivo Therapeutics Nomethiazoles as a treatment for rett syndrome
AU2020248351A1 (en) 2019-03-22 2021-11-11 Cognoa, Inc. Personalized digital therapy methods and devices
AU2020324396A1 (en) * 2019-08-05 2022-03-10 Neuren Pharmaceuticals Limited Compositions of trofinetide
EP4051308A4 (en) * 2019-10-28 2023-08-23 ACADIA Pharmaceuticals Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF RETT SYNDROME
WO2021217072A2 (en) * 2020-04-24 2021-10-28 New York University Use of igf-2 for treatment of epileptic seizures
IT202100004964A1 (it) * 2021-03-03 2022-09-03 Univ Degli Studi Di Bari Aldo Moro Agonisti del recettore fpr2 (formyl peptide receptor 2) e loro uso nel trattamento del disturbo dello spettro autistico.
KR20240035406A (ko) * 2021-07-12 2024-03-15 아카디아 파마슈티칼스 인코포레이티드 트로피네타이드의 결정형
CN114128672B (zh) * 2021-11-21 2023-04-07 河南省儿童医院郑州儿童医院 一种孤独症大鼠模型的构建方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
ATE12348T1 (de) 1980-11-10 1985-04-15 Gersonde Klaus Prof Dr Verfahren zur herstellung von lipid-vesikeln durch ultraschallbehandlung, anwendung des verfahrens und vorrichtung zur durchfuehrung des verfahrens.
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0142641B1 (de) 1983-09-26 1991-01-16 Udo Dr. Ehrenfeld Mittel und Erzeugnis für die Diagnose und Therapie von Tumoren sowie zur Behandlung von Schwächen der zelligen und humoralen Immunabwehr
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
DK15888D0 (da) 1988-01-14 1988-01-14 Carlsberg Biotechnology Ltd Enzymatisk fremgangsmaade til fremstilling af immunmodulerende pentapeptider samt mellemprodukter til brug ved fremgangsmaaden
SE8803847A0 (sv) 1988-10-27 1990-04-28 Kabigen Ab Neuromodulerande peptid
WO1995017204A1 (en) 1993-12-23 1995-06-29 Auckland Uniservices Limited Composition and methods to improve neural outcome
CA2190752A1 (en) 1994-05-24 1995-11-30 George N. Cox Modified insulin-like growth factors
WO1998014202A1 (en) 1996-10-04 1998-04-09 Auckland Uniservices Limited Regulation of neural enzymes
US6617311B1 (en) 1998-06-15 2003-09-09 Neuronz Limited Regulation of tyrosine hydroxylase
CA2388830C (en) * 1999-10-26 2006-09-19 Janssen Pharmaceutica N.V. Oral solution containing galanthamine and a sweetening agent
AU2001289160A1 (en) 2000-08-24 2002-03-04 Neuronz Ltd. Gpe analogs
US8637567B2 (en) 2001-05-24 2014-01-28 Neuren Pharmaceuticals Ltd. Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamic acid
US7863304B2 (en) 2001-05-24 2011-01-04 Neuren Pharmaceuticals Limited Analogs of glycyl-prolyl-glutamate
US7605177B2 (en) * 2001-05-24 2009-10-20 Neuren Pharmaceuticals Limited Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration
WO2006127702A2 (en) * 2005-05-23 2006-11-30 Neuren Pharmaceuticals Limited Analogs of glycyl-prolyl-glutamate
EP1401808B1 (en) 2001-05-24 2009-07-08 Neuren Pharmaceuticals Limited Gpe analogs and peptidomimetics
US20070004641A1 (en) * 2001-05-24 2007-01-04 Neuren Pharmaceuticals Limited Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamate
US7714020B2 (en) 2001-05-24 2010-05-11 Neuren Pharmaceuticals Limited Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate
US7714070B2 (en) 2002-08-27 2010-05-11 Sunoco Chemicals, Inc. In-reactor produced polypropylene blends
AU2005286943A1 (en) * 2004-09-20 2006-03-30 Mount Sinai School Of Medicine Use of memantine (NAMENDA) to treat autism, compulsivity, and impulsivity
WO2007106555A2 (en) * 2006-03-14 2007-09-20 Neuren Pharmaceuticals Limited Oral formulations of glycyl-2-methylprolyl-glutamate
GB0707127D0 (en) * 2007-04-13 2007-05-23 Zysis Ltd Pharmaceutical compositions
US7994127B2 (en) 2007-06-08 2011-08-09 Massachusetts Institute Of Technology Treatment of rett syndrome
TW200932233A (en) * 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
JP2011529072A (ja) 2008-07-24 2011-12-01 セラヴァンス， インコーポレーテッド 二重作用血圧降下薬
EP2387611A4 (en) 2009-01-16 2012-08-15 Massachusetts Inst Technology DIAGNOSIS AND TREATMENT OF AUTISTICAL DISEASES
WO2011146109A2 (en) 2010-05-17 2011-11-24 Mount Sinai School Of Medicine Methods and assays for treating subjects with shank3 deletion, mutation or reduced expression
US9708366B2 (en) 2011-01-27 2017-07-18 Neuren Pharmaceuticals Ltd. Treatment of fragile X syndrome using glycyl-L-2-methylprolyl-L-glutamate

Also Published As

Publication number Publication date
AU2012209466C1 (en) 2016-06-23
JP6348283B2 (ja) 2018-06-27
JP6640275B2 (ja) 2020-02-05
JP2014508744A (ja) 2014-04-10
EP2667715A1 (en) 2013-12-04
ES2641880T3 (es) 2017-11-14
US20140147491A1 (en) 2014-05-29
LT2667715T (lt) 2017-11-10
PT2667715T (pt) 2017-10-19
HRP20171478T1 (hr) 2017-11-17
JP2018138606A (ja) 2018-09-06
EP2667715B1 (en) 2017-07-19
BR112013018898A2 (pt) 2017-04-18
IL227669B (en) 2020-06-30
US20150197543A1 (en) 2015-07-16
WO2012102832A1 (en) 2012-08-02
JP2016210808A (ja) 2016-12-15
PL2667715T3 (pl) 2018-02-28
JP6342459B2 (ja) 2018-06-13
BR112013018898B1 (pt) 2021-10-05
DK2667715T3 (en) 2017-10-23
US9708366B2 (en) 2017-07-18
RS56461B1 (sr) 2018-01-31
HUE036637T2 (hu) 2018-07-30
EP2667715A4 (en) 2014-07-23
CA2823218C (en) 2021-04-20
CO6791613A2 (es) 2013-11-14
US9212204B2 (en) 2015-12-15
SI2667715T1 (sl) 2017-11-30
AU2012209466A1 (en) 2013-09-05
IL227669A0 (en) 2013-09-30
CA2823218A1 (en) 2012-08-02
AU2012209466B2 (en) 2016-02-25

Similar Documents

Publication Publication Date Title
CY1119455T1 (el) Θεραπεια διαταραχων του αυτιστικου φασματος με τη χρηση γλυκυλ-l-2-μεθυλοπρολυλ-l-γλουταμινικου οξεος
CY1123175T1 (el) Παραγωγα πιπεριδιν-4-υλ αζετιδινης ως αναστολεις jak1
CY1119485T1 (el) Αναστολεις ινδαζολης του σηματοδοτικου μονοπατιου wnt και θεραπευτικες χρησεις αυτων
CY1121695T1 (el) Ενωσεις και συνθεσεις ως αναστολεις κινασης c-kit
CY1124000T1 (el) Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες σε κρυσταλλικη μορφη
CY1122601T1 (el) Αναστολεις gsk3 και μεθοδοι χρησης αυτων
CY1119880T1 (el) Παραγωγα πυρρολοπυριμιδινης για χρηση στη θεραπεια ιικων λοιμωξεων
CY1111469T1 (el) ΧΡΗΣΗ ΠΑΡΑΓΩΓΩΝ 3-ΦΑΙΝΥΛΘΕΙΟ-1Η-ΙΝΔΟΛΗ-1-ΟΞΙΚΟΥ ΟΞΕΟΣ ΩΣ ΡΥΘΜΙΣΤΕΣ ΤΗΣ ΔΡΑΣΗΣ ΤΟΥ ΥΠΟΔΟΧΕΑ CRTh2
RU2711869C3 (ru) Имидазопирролопиразиновые производные, полезные для лечения заболеваний, вызванных аномальной активностью протеинкиназ Jak1, Jak3 или Syk
DE602006011910D1 (de) Neue glucopyranoseester und glucofuranoseester von fumarsäurealkylestern und deren pharmazeutische verwendung
EA200901212A1 (ru) 3-имидазолилиндолы, предназначенные для лечения пролиферативных заболеваний
CY1112369T1 (el) 2-μεθυλο-2-[4-(3-μεθυλο-2-οξο-8-κινολιν-3-υλο-2,3-διϋδρο-ιμιδαζο[4,5-c]κινολινυλο)-φαινυλο]προπιονιτριλιο ως αναστολεας λιπιδικης κινασης
CY1113642T1 (el) Γεφυρωμενες δικυκλικες ετεροαρυλ υποκατεστημενες τριαζολες, χρησιμες ως αναστολεις της axl
CY1114539T1 (el) Η χρησιμοτητα των ιμιδαζοπυριδαζινοκαρβονιτριλιων ως αναστολεων κινασων
EA201070988A1 (ru) Противовирусные терапевтические средства
CY1110977T1 (el) Υποκατεστημενα παραγωγα ινδολης για φαρμακευτικη συνθεση για θεραπεια ασθενειων του αναπνευστικου
ECSP12012326A (es) Derivados de aminopirimidina como moduladores de la lrrk2
EA201100440A1 (ru) Соединения, композиции и способы их применения для коррекции уровня мочевой кислоты
EA201490420A1 (ru) ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С α-СУБЪЕДИНИЦАМИ ПОТЕНЦИАЛЗАВИСИМЫХ НАТРИЕВЫХ КАНАЛОВ (SCNxA), С ПОМОЩЬЮ МАЛЫХ МОЛЕКУЛ
EA201201661A1 (ru) Новые аминопиразолохиназолины
CY1111758T1 (el) Τρικυκλικες ενωσεις και χρηση αυτων ως ρυθμιστες υποδοχεα γλυκοκορτικοειδους
EA201270339A1 (ru) Замещенные производные ксантина
AR077144A1 (es) Derivado de fenilimidazol como inhibidor de la enzima pde10a, composiciones farmaceuticas y uso de los mismos en el tratamiento de trastornos neurodegenerativos y psiquiatricos
CL2014000246A1 (es) Compuestos derivados fenil-3-aza-biciclo[3.1.0]hex-3-il-metanonas, inhibidores del transportador de glicina (glyt1); composicion farmaceutica que los contiene; combinacion farmaceutica; y su uso en el tratamiento de alzheimer, alteraciones cognitivas en esquizofrenia, psicosis, trastornos psiquiatricos, entre otros
ECSP045473A (es) Derivados de 1-(aminoalquil)-3-sulfonilindol y 1-aminoalquil-3-sulfonilindazol como ligandos de 5-hidroxitriptamina-6